AI IntelligenceJun 12, 2026Secondary Market
Article
映恩生物
The IPO application of biotech company映恩生物 (likely Duality Biologics) has been accepted for review. The Shanghai Stock Exchange has formally accepted the company's application to proceed with the listing process. This marks a significant step towards going public.
Data Cube AI EditorialSource: 36Kr
01
Source Brief
The IPO application of biotech company映恩生物 (likely Duality Biologics) has been accepted for review. The Shanghai Stock Exchange has formally accepted the company's application to proceed with the listing process. This marks a significant step towards going public.
02